Preview

Asco: Masitin Entry

Powerful Essays
Open Document
Open Document
1038 Words
Grammar
Grammar
Plagiarism
Plagiarism
Writing
Writing
Score
Score
Asco: Masitin Entry
EvaluatePharma - AB Science’s silence goes to the heart of masitinib’s ap...

http://www.evaluatepharma.com/Universal/View.aspx?type=Report&id=...

Welcome: Guest | Login or Register What are you looking for?
Search

Subscribers | Login Home Browse By Peer Groups Our Products Contact Us Careers
How We Use Cookies

AB Science’s silence goes to the heart of masitinib’s approvability
Source Company Tags Date EP Vantage AB Science Comment, Free Content, Company Strategy, Trial Results, Oncology January 28, 2013

The ASCO-GI conference has come and gone, and still key questions remain unanswered about the apparently stellar result from last year’s phase III pancreatic cancer study of AB Science’s masitinib. The company had earlier stated that at ASCO-GI it would reveal details about the robustness of the post-hoc analysis and the genetic biomarker that seems to correlate strongly with masitinib’s efficacy. But it now says that these will not be disclosed until later – a remarkable level of secrecy given that masitinib is already awaiting EU approval. The lingering unknowns, and AB’s refusal to shine a light on them, speak volumes about the project’s likelihood of a first-pass approval. On Friday AB presented a poster on the phase III study, adding masitinib on top of gemcitabine in 353 pancreatic cancer patients, at ASCO-GI. The company’s stock had surged on the announcement of topline data from this trial last October, but no detailed analysis was offered then, and little more is forthcoming now (AB Science's dog drug data raise more questions than answers, October 31, 2012). Trial failed Although the trial had unequivocally missed its primary endpoint, what had caused the excitement was the revelation that two subgroups – patients with pain above a certain threshold and those with a particular genetic marker – had done particularly well on masitinib, boosting median overall survival versus standalone gemcitabine with barely believable p values of 0.010

You May Also Find These Documents Helpful

  • Powerful Essays

    Alcohol Health

    • 3179 Words
    • 8 Pages

    References: Atherton, P., Jasperson, B., Nibbe, A., Clement-Brown, K., Allmer, C., Novotny, P., Erlichman, C. and Sloan, J. (2003). What Happened to All the Patients? Event Charts for Summarizing Individual Patient Data and Displaying Clinically Significant Changes in Quality of Life Data. Therapeutic Innovation & Regulatory Science, 37(1), pp.11-21.…

    • 3179 Words
    • 8 Pages
    Powerful Essays
  • Good Essays

    Early diagnosis can also transform the design and execution of clinical trials to test new treatments.…

    • 1221 Words
    • 4 Pages
    Good Essays
  • Satisfactory Essays

    Head Injuries in Football

    • 502 Words
    • 3 Pages

    Vande, Woude George F., and Georg Klein. Advances in Cancer Research. Amsterdam: Elsevier - Academic, 2007. Print.…

    • 502 Words
    • 3 Pages
    Satisfactory Essays
  • Powerful Essays

    JEMAL, A. 2011. Global Cancer Statistics. CA: A Cancer Journal for Clinicians, 61, 69 - 90.…

    • 1327 Words
    • 6 Pages
    Powerful Essays
  • Better Essays

    Gmo Lab Report

    • 2784 Words
    • 12 Pages

    Sylvia R. M. Broeders, Sigrid C. J. De Keersmaecker, and Nancy H. C. Roosen. "How to Deal with the Upcoming Challenges in." Journal of Biomedicine and Biotechnolog (2012): 11.…

    • 2784 Words
    • 12 Pages
    Better Essays
  • Powerful Essays

    In April 2000, the biopharmaceutical company Abgenix faced the important strategic decision of how to most profitably commercialize its XenoMouse based high potential cancer product ABX-EGF, which had reached phase I clinical trials after having successfully passed preclinicals.…

    • 1627 Words
    • 7 Pages
    Powerful Essays
  • Good Essays

    Pancreatic Cancer Essay

    • 445 Words
    • 2 Pages

    Pancreatic cancer is an aggressive type of cancer that will be diagnosed in approximately 53,070 Americans this year alone; 41,780 will die of it. (1) The pancreas is an organ essential in maintaining homeostasis in the body, it secretes hormones and enzymes that help us in the digestion of fats. Due to its “invasiveness, rapid progression and profound resistance to treatment” (3), pancreatic cancer is the fourth cause of cancer death in the United States.…

    • 445 Words
    • 2 Pages
    Good Essays
  • Better Essays

    Kleinsmith, L.J, Kerrigan, D, Kelly, J and Hollen, B (2004, September). Understanding Cancer and Related Topics. Slides 3-8. Retrieved August 12, 2008, from http://www.cancer.gov/cancertopics/understandingcancer/cancer/Slide1…

    • 1665 Words
    • 7 Pages
    Better Essays
  • Powerful Essays

    According to the National Cancer Institute, approximately 12.7 million people are diagnosed with cancer each year and 7.6 million of them die from this disease. People usually undergo chemotherapy, radiation therapy, immunotherapy and some go towards alternative treatment to prolong their life, ameliorate it or even save it. Lately, there has been a high number of patients who have refused to pursue chemotherapy even though there was a high chance of improvement…

    • 1674 Words
    • 7 Pages
    Powerful Essays
  • Good Essays

    Medmmune Case Study Essay

    • 678 Words
    • 3 Pages

    MedImmune is a biotechnology company based in Gaithersbug, Maryland. Currently the company has five products on the market: Synagis, CytoGam, RespiGam, Ethyol, and NeuTrexin. These medications target small markets of patients with auto-immune disorders, treating either respiratory illnesses or cancer. In addition, the company has several medications currently under development, including one in the preclinical phase, three in phase I of clinical trials, three in phase II trials, four in phase III, and one in phase IV efficacy trials. Due to the nature of the medical industry and regulations on testing and approval for drugs, it could be several years before any of these medications currently under development could obtain approval and be marketed.…

    • 678 Words
    • 3 Pages
    Good Essays
  • Satisfactory Essays

    With the recent dramatic increase in research in targeted therapies has come an increase in use of biomarker endpoints in all phases. These are not generally considered to be clinical benefit endpoints by the regulatory agencies.…

    • 80 Words
    • 1 Page
    Satisfactory Essays
  • Satisfactory Essays

    AIHW Cancer Case Study

    • 159 Words
    • 1 Page

    Cancer is second only to cardiovascular disease with respect to the mortality rate of the patients suffering with the disease. According to the statistics from AIHW (), it is estimated that about 126,800 new cancer cases will be diagnosed in 2015, in Australia, of which ~ 55% will be male. In their previous survey of 2012, AIHW had reported to have 43,039 death cases due to cancer among Australian population with 44% being females. This rate has been predicted to increase in 2015 to 46,570 with the relative projections of different cancer types being listed in the table T1. These projections indicate the urgency of consistent therapeutic needs to cure the disease, pathway to which has a number of challenges, biggest being the specific target…

    • 159 Words
    • 1 Page
    Satisfactory Essays
  • Good Essays

    Biocon

    • 673 Words
    • 2 Pages

    The market opportunity will be bigger in India because of the country’s improving economy (9% yearly) and increasing population (1.4% population growth rate). BIOMAb can also be marketed abroad and the international incidence is at least 7-8X that in India. BIOMAb may also be approved for other indications such as for colorectal cancer. The incidence rate for colorectal cancer in India in 2004 was 33,000 but internationally it was 1,023,000 and the 5-yr prevalence 2,830,000.…

    • 673 Words
    • 2 Pages
    Good Essays
  • Powerful Essays

    Tim Horton's Isp

    • 98563 Words
    • 395 Pages

    Source: Company Information as of ecember 0, 2012. ll mar et share data in this nnual Report is sourced from Crest data as of November 2012.…

    • 98563 Words
    • 395 Pages
    Powerful Essays
  • Good Essays

    RES 351 Wk 1

    • 793 Words
    • 2 Pages

    There were many injured parties in the case of GSK. To start the company was a huge injured party, as well as the company that did the clinical trials for them. The researchers were put under pressure by investigations that followed the discovery of GSK’s false reports. The negative attention alone can affect the trust others put in their research.…

    • 793 Words
    • 2 Pages
    Good Essays

Related Topics